About Tagomics

Tagomics develops a proprietary multiomic platform that utilizes genetic, epigenetic, and fragmentomic profiling to identify disease-associated biomarkers from various biological samples. This technology enables high-throughput and cost-effective diagnostics for early detection of colorectal and other common cancers, addressing the need for reliable biological markers sensitive to lifestyle and environmental factors.

```xml <problem> Current methods for detecting cancer biomarkers often lack sensitivity to lifestyle and environmental factors, and can be expensive and time-consuming. This can lead to delays in diagnosis and treatment, particularly for cancers like colorectal cancer that are influenced by environmental factors. </problem> <solution> Tagomics offers a multiomic platform that integrates genetic, epigenetic, and fragmentomic profiling to identify disease-associated biomarkers from biological samples. The platform uses advanced bioinformatic and machine learning approaches to provide insights into disease mechanisms and improve diagnostic accuracy. Tagomics' technology enables high-throughput and cost-effective multiomic disease profiling, with low sample input and automation capabilities. The platform is sample-agnostic and designed for reliable and reproducible results. </solution> <features> - Multiomic profiling platform integrating genetic, epigenetic, and fragmentomic data - Advanced bioinformatic and machine learning algorithms for biomarker discovery - High-throughput and cost-effective analysis - Low sample input requirements - Automatable workflow - Sample-agnostic design - Reliable and reproducible results - Interlace™ solution for multiomic profiling </features> <target_audience> The primary target audience includes researchers, clinicians, and pharmaceutical companies focused on early cancer detection and diagnosis, particularly for colorectal and other common cancers. </target_audience> ```

What does Tagomics do?

How much funding has Tagomics raised?

Tagomics has raised 10100000.

Funding

10100000

Employees

20 employees

Major Investors

Calculus Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Tagomics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

tagomics.com 2K+

Crunchbase

Funding

Estimated Funding

$10M+

Major Investors

Calculus Capital

Team (20+)

No team information available.

Company Description

Problem

Current methods for detecting cancer biomarkers often lack sensitivity to lifestyle and environmental factors, and can be expensive and time-consuming. This can lead to delays in diagnosis and treatment, particularly for cancers like colorectal cancer that are influenced by environmental factors.

Solution

Tagomics offers a multiomic platform that integrates genetic, epigenetic, and fragmentomic profiling to identify disease-associated biomarkers from biological samples. The platform uses advanced bioinformatic and machine learning approaches to provide insights into disease mechanisms and improve diagnostic accuracy. Tagomics' technology enables high-throughput and cost-effective multiomic disease profiling, with low sample input and automation capabilities. The platform is sample-agnostic and designed for reliable and reproducible results.

Features

Multiomic profiling platform integrating genetic, epigenetic, and fragmentomic data

Advanced bioinformatic and machine learning algorithms for biomarker discovery

High-throughput and cost-effective analysis

Low sample input requirements

Automatable workflow

Sample-agnostic design

Reliable and reproducible results

Interlace™ solution for multiomic profiling

Target Audience

The primary target audience includes researchers, clinicians, and pharmaceutical companies focused on early cancer detection and diagnosis, particularly for colorectal and other common cancers.